Skip to main content

Advertisement

Figure 2. | Chinese Journal of Cancer

Figure 2.

From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

Figure 2.

Proposed mechanisms accounting for resistance to inhibitors of the PI3K pathway. Selective blockade of mTORC1 by rapalogs increases mTORC2 and results in the positive feedback activation of pAkt. Inhibition of mTOR removes the basal inhibition of IRS-1, which is now free to bind to and activate IGF-1R and promote PI3K activation. In the presence of constitutive activation of KRAS, abrogation of the PI3K pathway alone does not inhibit cancer cell growth. IRS-1, insulin receptor substrate-1. Other abbreviations as in Figure 1.

Back to article page